Fluctuations in central retinal thickness appear to significantly affect best corrected visual acuity in patients with neovascular age-related macular degeneration, according to a study in the European Journal of Ophthalmology.
Francesco Ciucci, MD, and colleagues conducted a retrospective review of patient records to look at OCT data of 41 patients treated for neovascular AMD with aflibercept. Patients received injections every 4 weeks during the first 3 months and then received bimonthly injections over the first year before moving to an as-needed regimen.
“We focused our attention on